Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage’s lead product is approved by the U.S. Food and Drug Administration (FDA) for postpartum depression. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.
Jun 18, 2019
Copyright Nasdaq. Minimum 15 minutes delayed.
Copyright West LLC. Minimum 15 minutes delayed.
Events & Presentations
Jun 25, 2019 at 8:40 AM EDT
BMO Prescriptions for Success Healthcare Conference
Jun 11, 2019 at 11:00 AM EDT
Goldman Sachs 40th Annual Global Healthcare Conference
May 21, 2019 at 3:35 PM EDT
RBC Capital Markets 2019 Healthcare Conference